Clinical Trials Logo

Neovascular Macular Degeneration clinical trials

View clinical trials related to Neovascular Macular Degeneration.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02204683 Completed - Clinical trials for Neovascular Macular Degeneration

Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

DRAW
Start date: September 5, 2014
Phase: Phase 1
Study type: Interventional

The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.

NCT ID: NCT02120950 Completed - Clinical trials for Neovascular Macular Degeneration

Aflibercept in Polypoidal Choroidal Vasculopathy

PLANET
Start date: May 29, 2014
Phase: Phase 4
Study type: Interventional

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

NCT ID: NCT01245387 Completed - Clinical trials for Age-related Macular Degeneration

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration

MACULA
Start date: August 2006
Phase: N/A
Study type: Observational

Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.

NCT ID: NCT00590694 Completed - Clinical trials for Age-related Macular Degeneration

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

DETAIL
Start date: October 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis). The PrONTO study was the first ranibizumab study to enroll such patients but only treated with ranibizumab until fluid within the layers of the retina was absent, not until the entire PED was absent. This study hypothesizes that there may be a difference in benefit between patients treated until just the retinal edema is gone and those in which the retinal edema and PED are both gone.